IntelGenx Technologies Corp.
IGX
Rangering i aksjer
#28114
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aksjekurs
$0.17446996
Sist synkronisert: 2024-06-11
Markedsverdi
$26.97M
Endring (1 dag)
-0.57%
Endring (1 år)
2.63%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)
Kategori
Healthcare
Antall utestående aksjer for IntelGenx Technologies Corp. (IGX)
Antall utestående aksjer per March 2024: 174.66M
Ifølge IntelGenx Technologies Corp. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 174.66M. Ved slutten av December 2022 hadde selskapet 164.75M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for IntelGenx Technologies Corp. (IGX) fra 2003 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 174.66M | 0.00% |
| 2023 | 174.65M | 6.01% |
| 2022 | 164.75M | 20.25% |
| 2021 | 137.00M | 26.34% |
| 2020 | 108.44M | 15.95% |
| 2019 | 93.53M | 26.18% |
| 2018 | 74.12M | 12.05% |
| 2017 | 66.15M | 3.43% |
| 2016 | 63.96M | 0.68% |
| 2015 | 63.52M | 0.54% |
| 2014 | 63.18M | 16.95% |
| 2013 | 54.02M | 8.84% |
| 2012 | 49.64M | 13.49% |
| 2011 | 43.74M | 23.81% |
| 2010 | 35.33M | 44.02% |
| 2009 | 24.53M | 24.78% |
| 2008 | 19.66M | 22.53% |
| 2007 | 16.04M | 11.91% |
| 2006 | 14.34M | 30.42% |
| 2005 | 10.99M | 632.73% |
| 2004 | 1.50M | 0.00% |
| 2003 | 1.50M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 45.37% |
US
|
|
| 396.00M | 126.73% |
US
|
|
| 478.91M | 174.20% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -64.40% |
NL
|
